Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient.

Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. Clin Lymphoma Myeloma Leuk. 2014 Feb 4; Authors: Broccoli A, Pellegrini C, Celli M, Argnani L, Agostinelli C, Pileri S, Zinzani PL PMID: 24629851 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24629851?dopt=Abstract

Source: Clinical Lymphoma and Myeloma - February 4, 2014 Category: Cancer & Oncology Authors: Broccoli A, Pellegrini C, Celli M, Argnani L, Agostinelli C, Pileri S, Zinzani PL Tags: Clin Lymphoma Myeloma Leuk Source Type: research